| Scrip Code | 539872 |
|---|---|
| NSE Symbol | BAJAJHCARE |
| MSEI Symbol | NOTLISTED |
| ISIN | INE411U01027 |
| Name of company | BAJAJ HEALTHCARE LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 20-07-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 14-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceuticals |
| Start date and time of board meeting | 20-07-2026 17:00:00 |
| End date and time of board meeting | 20-07-2026 17:31:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| During the quarter ended 30 June 2026, there has been no default of any loan or debt securities. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 16,563.17 | 16,563.17 | |
| Other income | 81.14 | 81.14 | |
| Total income | 16,644.31 | 16,644.31 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 9,158.91 | 9,158.91 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (549.24) | (549.24) |
| (d) | Employee benefit expense | 1,747.12 | 1,747.12 |
| (e) | Finance costs | 609.10 | 609.10 |
| (f) | Depreciation, depletion and amortisation expense | 701.38 | 701.38 |
| (f) | Other Expenses | ||
| 1 | Brokerage & Commission | 101.82 | 101.82 |
| 2 | Consumption of Stores Spares and Maintainence | 673.25 | 673.25 |
| 3 | Freight Forwarding & Transport | 358.56 | 358.56 |
| 4 | Legal & Professional Expenses | 175.16 | 175.16 |
| 5 | Miscellaneous Expenses | 57.50 | 57.50 |
| 6 | Power and Fuel | 748.07 | 748.07 |
| 7 | Processing & Labour Charges | 580.99 | 580.99 |
| 8 | Provision for Credit Loss | 100.00 | 100.00 |
| 9 | Travelling & Conveyence Expenses | 66.83 | 66.83 |
| 10 | Others | 469.03 | 469.03 |
| Total other expenses | 3,331.21 | 3,331.21 | |
| Total expenses | 14,998.48 | 14,998.48 | |
| 3 | Total profit before exceptional items and tax | 1,645.83 | 1,645.83 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 1,645.83 | 1,645.83 |
| 6 | Tax expense | ||
| 7 | Current tax | 0.00 | 0.00 |
| 8 | Deferred tax | 256.55 | 256.55 |
| 9 | Total tax expenses | 256.55 | 256.55 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 1,389.28 | 1,389.28 |
| 12 | Profit (loss) from discontinued operations before tax | (26.03) | (26.03) |
| 13 | Tax expense of discontinued operations | (6.55) | (6.55) |
| 14 | Net profit (loss) from discontinued operation after tax | (19.48) | (19.48) |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 1,369.80 | 1,369.80 |
| 17 | Other comprehensive income net of taxes | 22.45 | 22.45 |
| 18 | Total Comprehensive Income for the period | 1,392.25 | 1,392.25 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,683.13 | 1,683.13 | |
| Face value of equity share capital | 5 | 5 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 4.13 | 4.13 | |
| Diluted earnings (loss) per share from continuing operations | 4.12 | 4.12 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | -0.06 | -0.06 | |
| Diluted earnings (loss) per share from discontinued operations | -0.06 | -0.06 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 4.07 | 4.07 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 4.06 | 4.06 | |
| 24 | Debt equity ratio | 46.00 | 46.00 |
| 25 | Debt service coverage ratio | 247.3400 | 247.3400 |
| 26 | Interest service coverage ratio | 370.2100 | 370.2100 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above financial results of Bajaj Healthcare Limited (the Company) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 20 July 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion. 2. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 3. The above unaudited financial results for the quarter ended 30 June 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS)as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations 2015 as amended. 4. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore the Company has identified only one reportable segment i.e. Pharmaceuticals. 5. In the year ended 31 March 2024 the Board of Directors had approved to sale disposal of undertaking unit(s) on going concern basis situated at plot no. N 92, L 9 3, T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 and D 2 CH 43 Dahej industrial area GIDC Bharuch Gujarat (which were acquired under SARFAESI ACT 2022 from Saraswat Bank) and plot no.E 62 and E 63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 (Non-current Assets Held for Sale and Discontinued Operations). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and L 9 3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value. The financial information from discontinued operations: Particulars Quarter Ended Year ended 30 June 2026 31 March 2026 30 June 2025 31 March 2026 (Unaudited) (Refer Note 2) (Unaudited) (Audited) Total Income ( A ) 10.61 2.10 11.71 Total Expenses ( B ) 26.03 240.79 47.53 523.40 Loss before Tax from Discontinued Operations ( C A B ) (26.03) (230.18) (45.43) (511.69) Tax Credit from Discontinued Operations ( D ) (6.55) 113.60 (11.43) 42.74 Loss after Tax from Discontinued Operations ( E = C D ) (19.48) (343.78) (34.00) (554.43) 6. On 19 September 2024 the Company allotted 3984852 equity shares and 2079409 convertible warrants raising an aggregate amount of Rs. 15225.90 lakhs. This included 25 percent of the warrant issue price amounting to Rs. 1757.10 lakhs received at the time of allotment of the convertible warrants. During the quarter ended 31 March 2026 the Company received the balance 75 percent of the warrant issue price aggregating Rs. 5271.30 lakhs. Subsequently the Board of Directors at its meeting held on 18 March 2026 approved the conversion of all 2079409 convertible warrants into an equivalent number of fully paid up equity shares of face value Rs. 5 each. Pursuant to the aforesaid conversion the issued subscribed and paid up equity share capital of the Company increased from Rs. 1579.16 lakhs comprising 31583252 equity shares of face value Rs. 5 each to Rs. 1683.13 lakhs comprising 33662661 equity shares of face value Rs. 5 each. During the quarter ended 30 June 2026 the Company received approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for the listing and trading of the aforesaid 2079409 equity shares of face value Rs. 5 each. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. Particulars Amount to be Utilised Utilised up to 30 June 2026 Unutilised Balance Repayment of loan 15000.00 15000.00 0.00 Investment in capital expenditure 3500.00 2330.84 1169.16 General corporate purposes 1997.00 1993.48 3.52 Total 20497.00 19324.32 1172.68 7. The Company had entered into a Transfer of Technical Know how arrangement with a customer for one of the products manufactured by the Company. The Technical know how was ultimately to be used by a customer in Middle East. Due to on going regional instability in Middle East the customer was not able to meet its committed timeline. Hence the Company has reversed the income recognised in earlier year amounting to Rs. 3324.66 lakhs in the quarter ended 31 March 2026. 8. In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (Genrx) on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act 1956. The acquisition was made for a total consideration of Rs. 1085.00 lakhs. Subsequently on 3 June 2025 the Company filed an application with the Honble National Company Law Tribunal (NCLT) Mumbai seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern which is pending with NCLT as on 30 June 2026. Hence Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110 Consolidated Financial Statements is not established. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | Debt Service Coverage Ratio is annualized |
| Interest service coverage ratio | Interest Service Coverage Ratio indicates adequate coverage of finance costs. |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement of defined benefit plans | 30.00 | 30.00 |
| Total Amount of items that will not be reclassified to profit and loss | 30.00 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 7.55 | 7.55 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 22.45 | 22.45 |
| Mode of Fund Raising | Others |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 18-03-2026 |
| Amount Raised | 5,271.30 |
| Report filed for Quarter ended | 30-06-2026 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | CARE Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | Not Applicable |
| Comments of the Audit Committee after review | No Comments |
| Comments of the auditors, if any | No Comments |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Repayment & Prepayment of Secured/Unsecured Loans from Bank/NBFC in part or in full | Not Applicable | 15,000.00 | 15,000.00 | 15,000.00 | 0.00 | |
| 2 | Investment in Capital Expenditure | Not Applicable | 3,500.00 | 3,500.00 | 2,330.84 | 0.00 | |
| 3 | General Corporate Purpose | Not Applicable | 2,200.00 | 1,997.00 | 1,993.48 | 0.00 |
| Name of signatory | Rohan Parekh |
| Designation of person | Chief Financial Officer |
| Place | Thane |
| Date | 20-07-2026 |